

DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL METHOD FOR THE QUANTIFICATION OF CLOPIDOGREL IN HUMAN PLASMA BY LC-MS/MS USING THE ACCURACY PROFILE

CHOUKRI EL KHABBAZ, AIMEN EL ORCHE, MUSTAPHA BOUATIA, AMINE CHEIKH,
MY EL ABBES FAOUZI, YAHIA CHERRAH, RATIBA BOUSSEN, HOUDA BOUCHAFRA

References:

1. Clopidogrel | European Medicines Agency <https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/clopidogrel-0> (accessed 2021 -12 -12).
2. Clarke, T. A.; Waskell, L. A. The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin. *Drug Metab. Dispos.* 2003, 31 (1), 53–59. <https://doi.org/10.1124/dmd.31.1.53>.
3. Savi, P.; Combalbert, J.; Gaich, C.; Rouchon, M. C.; Maffrand, J. P.; Berger, Y.; Herbert, J. M. The Antiaggregating Activity of Clopidogrel Is Due to a Metabolic Activation by the Hepatic Cytochrome P450-1A. *Thromb. Haemost.* 1994, 72 (2), 313–317.
4. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M. Identification and Biological Activity of the Active Metabolite of Clopidogrel. *Thromb. Haemost.* 2000, 84 (11), 891–896. <https://doi.org/10.1055/s-0037-1614133>.
5. Filipe, A.; Almeida, S.; Spínola, A. C. F.; Neves, R.; Tanguay, M.; Jiménez, C.; Shink, E. Single-Dose Randomized, Open-Label, 2-Way Crossover Bioequivalence Study of Clopidogrel 75 Mg Tablet in Healthy Volunteers under Fasting Conditions. *Int J. Clin. Pharmacol. Ther.* 2009, 47 (03), 187–194. <https://doi.org/10.5414/CP47187>.
6. Di Girolamo, G.; Czerniuk, P.; Bertuola, R.; Keller, G. A. Bioequivalence of Two Tablet Formulations of Clopidogrel in Healthy Argentinian Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study. *Clin. Ther.* 2010, 32 (1), 161–170. <https://doi.org/10.1016/j.clinthera.2010.01.010>.
7. Lainesse, A.; Ozalp, Y.; Wong, H.; Alpan, R. Bioequivalence Study of Clopidogrel Bisulfate Film-Coated Tablets. *Arzneimittelforschung* 2011, 54 (09), 600–604. <https://doi.org/10.1055/s-0031-1297056>.
8. Brvar, N.; Lachance, S.; Lévesque, A.; Breznik, M.; Cvitkovič Marčič, L.; Merslavič, M.; Grabnar, I.; Mateovič-Rojnik, T. Comparative Bioavailability of Two Oral Formulations of Clopidogrel: Determination of Clopidogrel and Its Carboxylic Acid Metabolite (SR26334) under Fasting and Fed Conditions in Healthy Subjects. *Acta Pharm.* 2014, 64 (1), 45–62. <https://doi.org/10.2478/acph-2014-0001>.
9. Richter, W.; Erenmemisoglu, A.; Meer, M.; Emritte, N.; Emine, T.; Koytchev, R. Bioequivalence Study of Two Different Clopidogrel Bisulfate Film-Coated Tablets. *Arzneimittelforschung* 2011, 59 (06), 297–302. <https://doi.org/10.1055/s-0031-1296400>.
10. Savakula, S.; Pilli, N. R. Pharmacokinetic and bioequivalence comparison between clopidogrel bisulfate tablets 300mg: an open label, balanced, randomized-sequence, single- dose, two-period crossover study in healthy male volunteers. 9.
11. Setiawati, E.; Yunaidi, D.; Handayani, L.; Santoso, I.; Setiawati, A.; Tjandrawinata, R. Bioequivalence Study of Two Clopidogrel Film-Coated Tablet Formulations in Healthy Volunteers. *Arzneimittelforschung* 2012, 61 (12), 681–684. <https://doi.org/10.1055/s-0031-1300587>.
12. Silvestro, L.; Gheorghe, M.; Iordachescu, A.; Ciuca, V.; Tudoroni, A.; Rizea Savu, S.; Tarcomnicu, I. Development and Validation of an HPLC–MS/MS Method to Quantify Clopidogrel Acyl Glucuronide, Clopidogrel Acid Metabolite, and Clopidogrel in Plasma Samples Avoiding Analyte Back-Conversion. *Anal. Bioanal. Chem.* 2011, 401 (3), 1023–1034. <https://doi.org/10.1007/s00216-011-5147-4>.
13. Zaid, A. N.; Al Ramahi, R.; Bustami, R.; Mousa, A.; Khasawneh, S. Comparative Fasting Bioavailability of Two Clopidogrel Formulations in Healthy Mediterranean Volunteers: An in Vitro&dashin Vivo Correlation. *Drug Des. Devel. Ther.* 2015, 2359. <https://doi.org/10.2147/DDDT.S78658>.
14. Zou, J.-J.; Fan, H.-W.; Guo, D.-Q.; Li, Y.-B.; Lin, S.; Zhu, Y.-B.; Yu, C.-X.; Zhou, J.; Liu, J.-H.; Hu, Y.-F. Simultaneous Determination of Clopidogrel and Its Carboxylic Acid Metabolite (SR26334) in Human Plasma by LC–ESI–MS–MS: Application to the Therapeutic Drug Monitoring of Clopidogrel. *Chromatographia* 2009, 70 (11–12), 1581–1586. <https://doi.org/10.1365/s10337-009-1349-8>.
15. Peer, C. J.; Spencer, S. D.; VanDenBerg, D. A. H.; Pacanowski, M. A.; Horenstein, R. B.; Figg, W. D. A Sensitive and Rapid Ultra HPLC–MS/MS Method for the Simultaneous Detection of Clopidogrel and Its Derivatized Active Thiol Metabolite in Human Plasma. *J. Chromatogr. B* 2012, 880, 132–139. <https://doi.org/10.1016/j.jchromb.2011.11.029>.
16. Liu, G.; Dong, C.; Shen, W.; Lu, X.; Zhang, M.; Gui, Y.; Zhou, Q.; Yu, C. Development and Validation of an HPLC–MS/MS Method to Determine Clopidogrel in Human Plasma. *Acta Pharm. Sin. B* 2016, 6 (1), 55–63. <https://doi.org/10.1016/j.apsb.2015.11.001>.

17. Kim, S.-D.; Kang, W.; Lee, H. W.; Park, D. J.; Ahn, J. H.; Kim, M. J.; Kim, E. Y.; Kim, S. W.; Nam, H. S.; Na, H. J.; Yoon, Y.-R. Bioequivalence and Tolerability of Two Clopidogrel Salt Preparations, Besylate and Bisulfate: A Randomized, Open-Label, Crossover Study in Healthy Korean Male Subjects. *Clin. Ther.* 2009, **31** (4), 793–803. <https://doi.org/10.1016/j.clinthera.2009.04.017>.
18. Karażniewicz-Łada, M.; Danielak, D.; Teżyk, A.; Żaba, C.; Tuffal, G.; Głowska, F. HPLC–MS/MS Method for the Simultaneous Determination of Clopidogrel, Its Carboxylic Acid Metabolite and Derivatized Isomers of Thiol Metabolite in Clinical Samples. *J. Chromatogr. B* 2012, **911**, 105–112. <https://doi.org/10.1016/j.jchromb.2012.11.005>.
19. Bahrami, G.; Mohammadi, B.; Sisakhtnezhad, S. High-Performance Liquid Chromatographic Determination of Inactive Carboxylic Acid Metabolite of Clopidogrel in Human Serum: Application to a Bioequivalence Study. *J. Chromatogr. B* 2008, **864** (1–2), 168–172. <https://doi.org/10.1016/j.jchromb.2008.01.049>.